1.

Molluscum contagiosum in Dutch general practice

2.

Molluscum contagiosum in Dutch general practice

3.

Molluscum contagiosum in Dutch general practice

4.

Molluscum contagiosum in Dutch general practice

5.

Molluscum contagiosum in Dutch general practice

1.

Plasma polychlorinated biphenyl levels in Dutch preschool children either breast-fed or formula-fed during infancy

2.

Plasma polychlorinated biphenyl levels in Dutch preschool children either breast-fed or formula-fed during infancy

3.

Plasma polychlorinated biphenyl levels in Dutch preschool children either breast-fed or formula-fed during infancy

4.

Plasma polychlorinated biphenyl levels in Dutch preschool children either breast-fed or formula-fed during infancy

5.

Plasma polychlorinated biphenyl levels in Dutch preschool children either breast-fed or formula-fed during infancy

1.

Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree

2.

Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree

3.

Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree

4.

Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree

5.

Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree

1.

Effects of perinatal exposure to PCBs and dioxins on play behavior in Dutch children at school age

2.

Effects of perinatal exposure to PCBs and dioxins on play behavior in Dutch children at school age

3.

Effects of perinatal exposure to PCBs and dioxins on play behavior in Dutch children at school age

4.

Effects of perinatal exposure to PCBs and dioxins on play behavior in Dutch children at school age

5.

Effects of perinatal exposure to PCBs and dioxins on play behavior in Dutch children at school age

1.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

2.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

3.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

4.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

5.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

6.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

7.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

8.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

9.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

1.

Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 t...

2.

Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 t...

3.

Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 t...

4.

Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 t...

5.

Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 t...

6.

Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 t...

7.

Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 t...

8.

Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 t...

9.

Health effects of environmental exposure to cadmium: objectives, design and organization of the Cadmibel Study: a cross-sectional morbidity study carried out in Belgium from 1985 t...

1.

Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium

2.

Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium

3.

Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium

4.

Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium

5.

Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium

1.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

2.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

3.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

4.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

5.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

6.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

7.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

8.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

9.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

1.

Organ donation in Belgium 2011: the highest donation rate ever

2.

Organ donation in Belgium 2011: the highest donation rate ever

3.

Organ donation in Belgium 2011: the highest donation rate ever

4.

Organ donation in Belgium 2011: the highest donation rate ever

5.

Organ donation in Belgium 2011: the highest donation rate ever

6.

Organ donation in Belgium 2011: the highest donation rate ever

7.

Organ donation in Belgium 2011: the highest donation rate ever

8.

Organ donation in Belgium 2011: the highest donation rate ever

9.

Organ donation in Belgium 2011: the highest donation rate ever

1.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

2.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

3.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

4.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

5.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

6.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

7.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

8.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.

9.

Neonatal screening improves sickle cell disease clinical outcome in Belgium.